More on the News
Natera will provide customized real-world data analyses using its oncology database, which combines more than two million plasma timepoints with clinical and imaging records. By combining molecular response data from Signatera with electronic medical records, the platform can generate insights into treatment response, disease progression and patient outcomes, supporting future clinical development and biomarker-driven strategies for leronlimab.
The collaboration follows the completion of patient enrollment in the CLOVER study, which is investigating leronlimab in combination with trifluridine/tipiracil (TAS-102) and bevacizumab for previously treated mCRC patients. The partnership is expected to complement ongoing biomarker and translational research from the study to further characterize treatment response and guide future development plans.
https://www.zacks.com/stock/news/2934120/ntra...nt-in-mcrc